Senores Pharmaceuticals Limited has announced the successful completion of its acquisition of 8,454 equity shares in Havix Group Inc., doing business as Aavis Pharmaceuticals. This marks the final step in a transaction that began in March 2025, as disclosed in a recent regulatory filing.

Acquisition Details

The acquisition was executed in two phases:

1. Direct Acquisition: Senores Pharmaceuticals directly acquired 7,914 shares of Havix Group Inc.
2. Subsidiary Acquisition: The remaining 540 shares were acquired through Senores Pharmaceuticals Inc., the company's wholly-owned US subsidiary.

Regulatory Compliance

The split acquisition strategy was necessitated by regulatory requirements from the Reserve Bank of India (RBI). The company had to obtain specific approvals for the acquisition of the final 540 shares through its US subsidiary, which explains the phased approach to the transaction.

Timeline of Events

• March 11 and 12, 2025: Initial intimations regarding the planned acquisition of 8,454 equity shares from certain public shareholders of Havix Group Inc.
• April 22 and June 23, 2025: Updates on the progress of the acquisition, noting that 7,914 shares had been acquired directly, with the remaining 540 shares pending due to RBI approval requirements.
• September 12, 2025: Final announcement of the completion of the acquisition, including the purchase of the remaining 540 shares through the US subsidiary.

Management Statement

Vinay Kumar Mishra, Company Secretary and Compliance Officer of Senores Pharmaceuticals Limited, confirmed the completion of the transaction in the regulatory filing, stating, "Upon acquisition of said 540 equity shares, the transaction of acquisition for 8,454 equity shares stands completed."

About Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited is headquartered in Ahmedabad, Gujarat, India. The company is listed on both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE). With this acquisition, Senores Pharmaceuticals has expanded its presence in the pharmaceutical sector, potentially strengthening its position in the market.

The completion of this acquisition marks a significant milestone for Senores Pharmaceuticals, potentially enhancing its product portfolio and market reach through the integration with Havix Group Inc., operating as Aavis Pharmaceuticals.

Senores Pharmaceuticals announced that its material subsidiary, Havix Group Inc. D/B/A Aavis Pharmaceuticals ("Havix"), has successfully completed a United States Food & Drug Administration (USFDA) inspection at its manufacturing facility in Hoschton, Georgia, USA.

Inspection Details

The USFDA inspection took place from July 21 to July 25, 2025, at Havix's facility located at 9488 Jackson Trail Road, Hoschton, Georgia. The inspection concluded with three Form 483 observations, which the company described as procedural and minor in nature.

Company Response

Havix has been given a 15-day window to respond to these observations from the regulatory authority. The company has confirmed its intention to address these issues within the stipulated timeframe.

Management Statement

In a regulatory filing, Vinay Kumar Mishra, Company Secretary and Compliance Officer of Senores Pharmaceuticals Limited, stated, "These observations are procedural and minor in nature and Havix will respond to these observations within 15 days."

About Senores Pharmaceuticals

Senores Pharmaceuticals Limited is headquartered in Ahmedabad, Gujarat, India. The company, with its material subsidiary Havix, operates in the pharmaceutical sector. Havix's manufacturing facility in the United States plays a crucial role in the company's operations and regulatory compliance.

This USFDA inspection and its outcome are significant for Senores Pharmaceuticals and its subsidiary, as they reflect on the company's manufacturing practices and regulatory standing in the important US market.

Investors and stakeholders will likely be watching closely for any updates on the company's response to the USFDA observations and any potential impact on its operations or market position.